Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-chain amin...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2022-10-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/80638 |
| _version_ | 1828106971098644480 |
|---|---|
| author | Yasuyuki Tamai Akiko Eguchi Ryuta Shigefuku Hiroshi Kitamura Mina Tempaku Ryosuke Sugimoto Yoshinao Kobayashi Motoh Iwasa Yoshiyuki Takei Hayato Nakagawa |
| author_facet | Yasuyuki Tamai Akiko Eguchi Ryuta Shigefuku Hiroshi Kitamura Mina Tempaku Ryosuke Sugimoto Yoshinao Kobayashi Motoh Iwasa Yoshiyuki Takei Hayato Nakagawa |
| author_sort | Yasuyuki Tamai |
| collection | DOAJ |
| description | Background: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-chain amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition.
Methods: The correlation between serum BA levels and psoas muscle mass index (PMI) was examined in 73 CLD patients. Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy.
Results: In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist.
Conclusions: Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival.
Funding: This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115. Maintaining cirrhotic rats were partially supported by Otsuka Pharmaceutical Company. |
| first_indexed | 2024-04-11T10:25:06Z |
| format | Article |
| id | doaj.art-9d9ad1ffcbca4c8bab44dc5bb9f59cc8 |
| institution | Directory Open Access Journal |
| issn | 2050-084X |
| language | English |
| last_indexed | 2024-04-11T10:25:06Z |
| publishDate | 2022-10-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj.art-9d9ad1ffcbca4c8bab44dc5bb9f59cc82022-12-22T04:29:38ZengeLife Sciences Publications LtdeLife2050-084X2022-10-011110.7554/eLife.80638Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humansYasuyuki Tamai0https://orcid.org/0000-0002-8012-8578Akiko Eguchi1https://orcid.org/0000-0002-0555-2707Ryuta Shigefuku2Hiroshi Kitamura3Mina Tempaku4Ryosuke Sugimoto5Yoshinao Kobayashi6https://orcid.org/0000-0003-2447-684XMotoh Iwasa7Yoshiyuki Takei8Hayato Nakagawa9Department of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Veterinary Medicine, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanCenter for Physical and mental health, Mie University Graduate School of Medicine, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanDepartment of Gastroenterology and Hepatology, Graduate school of medicine, Mie University, Tsu, JapanBackground: Hepatic sarcopenia is one of many complications associated with chronic liver disease (CLD) and has a high mortality rate; however, the liver-muscle axis is not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best of which being branched-chain amino acid (BCAA) supplementation to help increase muscle mass. Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on bile acid (BA) composition. Methods: The correlation between serum BA levels and psoas muscle mass index (PMI) was examined in 73 CLD patients. Gastrocnemius muscle phenotype and serum BA levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12) were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or TGR5 antagonist to assess skeletal muscle hypertrophy. Results: In human CLD, serum LCA levels were the sole factor positively correlated with PMI and were significantly decreased in both the low muscle mass group and the deceased group. Serum LCA levels were also shown to predict patient survival. Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via suppression of protein degradation pathways, coupled with a significant increase in serum LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist. Conclusions: Our results indicate LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling pathways. In addition, serum LCA levels were associated with skeletal muscle mass in cirrhotic rats, as well as CLD patients, and predicted overall patient survival. Funding: This research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115. Maintaining cirrhotic rats were partially supported by Otsuka Pharmaceutical Company.https://elifesciences.org/articles/80638chronic liver diseaseslow muscle massskeletal musclebile acidslithocholic acidliver-muscle axis |
| spellingShingle | Yasuyuki Tamai Akiko Eguchi Ryuta Shigefuku Hiroshi Kitamura Mina Tempaku Ryosuke Sugimoto Yoshinao Kobayashi Motoh Iwasa Yoshiyuki Takei Hayato Nakagawa Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans eLife chronic liver diseases low muscle mass skeletal muscle bile acids lithocholic acid liver-muscle axis |
| title | Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans |
| title_full | Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans |
| title_fullStr | Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans |
| title_full_unstemmed | Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans |
| title_short | Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans |
| title_sort | association of lithocholic acid with skeletal muscle hypertrophy through tgr5 igf 1 and skeletal muscle mass in cultured mouse myotubes chronic liver disease rats and humans |
| topic | chronic liver diseases low muscle mass skeletal muscle bile acids lithocholic acid liver-muscle axis |
| url | https://elifesciences.org/articles/80638 |
| work_keys_str_mv | AT yasuyukitamai associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT akikoeguchi associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT ryutashigefuku associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT hiroshikitamura associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT minatempaku associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT ryosukesugimoto associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT yoshinaokobayashi associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT motohiwasa associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT yoshiyukitakei associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans AT hayatonakagawa associationoflithocholicacidwithskeletalmusclehypertrophythroughtgr5igf1andskeletalmusclemassinculturedmousemyotubeschronicliverdiseaseratsandhumans |